Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Arms (1)

1. type

   EXPERIMENTAL

   label

   1

   interventionNames

   1. Drug: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
   2. Drug: Sunitinib

Primary outcomes (1)

1. measure

   Progression-Free Survival (PFS)

   timeFrame

   Up to 11 cycles (1 cycle = 6 weeks)

   description

   PFS is defined as the time from the date of enrollment to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first. PFS data was censored on the day following the date of the last tumor assessment documenting absence of progressive disease for patients who 1) were given anti-tumor treatment other than the study treatment prior to observing objective tumor progression; 2) were removed from the study prior to documentation of objective tumor progression; and 3) were ongoing at the time of the analysis.